Infantile hemangioma

Propranolol

VEGF receptors

Receptor

Cancer research

Vascular Tumors

Hemangiosarcoma

Internal medicine

Oncology

Medicine

Vascular tumor

Hemangioma

Cancer

Sarcoma

Angiosarcoma

Pathology

Journal of Experimental Pharmacology

Abstract: Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers. Keywords: propranolol, vascular sarcoma, angiosarcoma, β-blocker, cancer

Propranolol for the treatment of vascular sarcomas